Are anti-phospholipid antibodies associated with response to interferon-beta1a treatment in MS : results from a 3-year longitudinal study?
This study suggests that APLA(+) RRMS patients treated with IFN-beta1a develop more severe MRI and clinical deterioration. Future studies are required to evaluate the role of APLA as potential biomarkers for disease prognosis versus predictors for therapeutic response to IFN-beta therapy.
The expression of IGFBP-1 in CCA is more specific than that of HNF-1β. IGFBP-1 shows expression by decidual endometrium and Arias-Stella glands, and CCA also exhibits characteristic expression. These results indicate that IGFBP-1 is a immunohistochemical marker for CCA.